Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
Mînzu, V. and Arama, I. (2025) A New Method to Predict the Mechanical Behavior for a Family of Composite Materials. Journal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback